ALX4 and adenoma: Similar observations of increased adenoma detection have been observed for the well-studied methylation biomarker, SEPT9 when studied in a small cohort of 76 cases in conjunction with another methylation marker, ALX4. The additional of ALX4 increased sensitivity for advanced precancerous colorectal lesions from 12 to 45% (6/49 vs. 22/49) [24, 40] compared to SEPT9 alone.